Scott Woods, MD
Enriched profileElizabeth Mears and House Jameson Professor of Psychiatry; Professor of Psychiatry, Yale School of Medicine; Director, PRIME Psychosis Prodrome Research Clinic · Yale University School of Medicine
Scott Woods is Elizabeth Mears and House Jameson Professor of Psychiatry; Professor of Psychiatry, Yale School of Medicine; Director, PRIME Psychosis Prodrome Research Clinic at Yale University School of Medicine. OpenAlex indexes 742 publications with 35,769 citations (h-index 93); ClinicalTrials.gov lists 19 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Psychiatry profiles in the findmyKOL directory. Clarivate lists Scott Woods as a Highly Cited Researcher (Psychiatry and Psychology, 2019-2022; Psychiatry/Psychology, 2014-2018).
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Scott Woods, MD, is Elizabeth Mears and House Jameson Professor of Psychiatry at Yale University School of Medicine, Department of Psychiatry. The public record shows 742 publications with 35,769 citations (h-index 93), centered on Schizophrenia research and treatment, Mental Health and Psychiatry, Bipolar Disorder and Treatment. It also documents an investigator role on 19 registered clinical trials, industry payments reported by 2 companies, 16 NIH-funded awards (1989–2026).
- Most recent indexed publication: 2026 · Early intervention in psychiatry
- Top research focus: Schizophrenia research and treatment
- 19 registered trials on ClinicalTrials.gov
- Open Payments reporting from 2 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 37 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 377.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cga.ct.gov ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 19 registered studies on ClinicalTrials.gov. The most recent:
- A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis
Sponsor: Monument Therapeutics Limited
- AMP SCZ® Observational Study: PREDICT-DPACC
Sponsor: Brigham and Women's Hospital
- Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial
Sponsor: University of California, Los Angeles
Industry payments
Updated 27 Aug 2026
2 companies reported payments to CMS in program years 2024–2025. These are public disclosures, not judgments. The latest:
- RTI SURGICAL, INCProgram year20251 payment
- Phathom Pharmaceuticals, Inc.Program year20241 payment
Medicare prescribing footprint (2020)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%Atypical Antipsychotic24.4%Quetiapine Fumarate58%Risperidone16%Ziprasidone Hcl13%Aripiprazole13%Part D<11 patientsBenzodiazepine17.7%Lorazepam50%Clonazepam50%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
16 NIH research awards on record, funded 1989–2026 per NIH RePORTER. The latest:
- ProCAN: Psychosis Risk Outcomes Compound Assessment Network
Yale University
FY2026$17,070,000U01MH137298
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Exploring Group Differences in Attenuated Symptoms and Functioning Between Clinical High-Risk Individuals With and Without Posttraumatic Stress Disorder.
Early intervention in psychiatry
Article2026 - Guidelines for the prevention of psychosis from the World Federation of Societies of Biological Psychiatry (WFSBP) and EPI Canada.
The world journal of biological psychiatry
Guideline2026 - Association of Fetal Gene Regulatory Gene Deletions With Poor Cognition in Schizophrenia and Community-Based Samples.
The American journal of psychiatry
Article2026 - Using connectome-based predictive models to reveal the systems standardized tests and clinical symptoms are reflecting.
Nature communications
Article2026 - Value representation in youth psychopathology: evidence of a transdiagnostic risk mechanism for psychosis.
Translational psychiatry
Article2026
Most-cited works
by citation count (OpenAlex)- 01Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics2,058 citations2003
- 02Prediction of Psychosis in Youth at High Clinical Risk1,271 citations2008
- 03Multicenter Collaborative Panic Disorder Severity Scale1,016 citations1997
- 04
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/scott-woods-md-40901003
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/scott-woods-77ab6823
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
medicine.yale.edu/profile/scott-woods
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
Mentions by others
where others cite or feature them- Other
apaf.org/library-archives/galleries/alexander-gralnick-award/scott-woods-m-d-ph-d
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →apaf.org ↗ - Other
medscape.com/viewarticle/984484
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medscape.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
Editorial & leadership roles
journal and society appointments- Director
PRIME Psychosis Prodrome Research Clinic, Yale Department of Psychiatry
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - Co-developer of the Structured Interview for Psychosis Risk Syndromes (SIPS)
with Thomas McGlashan, Barbara Walsh, and Tandy Miller
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Psychiatry and Psychology2019202020212022verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
- Psychiatry/Psychology20142015201620172018verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- NIH ProCAN grant ($76M, 2023)
Psychosis-Risk Outcomes Compound Assessment Network, co-led with Youngsun Cho
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - 2021 Alexander Gralnick Award for Research in Schizophrenia
American Psychiatric Association Foundation
2021verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →apaf.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →apaf.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ynhhs.org ↗
Media & interviews
press, podcasts and appearances- Guest
Medscape "InDiscussion" podcast series on schizophrenia, S2 Episode 4: "Schizophrenia, Clinical High-risk Syndrome, and Psychosis" (with host Dr. John Kane), published August 16
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medscape.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care